Evaluation of rectal dose discrepancies between planned and in vivo dosimetry using MOSkin detector and PTW 9112 semiconductor probe during 60Co HDR CT-based intracavitary cervix brachytherapy |
| |
| Institution: | 1. Medical Physics Unit, University of Malaya Medical Centre, Kuala Lumpur 59100, Malaysia;2. Department of Clinical Oncology, University of Malaya Medical Centre, Kuala Lumpur 59100, Malaysia;3. Clinical Oncology Unit, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia;4. Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia;1. Leeds Cancer Centre, Leeds, UK;2. Currently at Imperial College Healthcare NHS Trust, London, UK;3. University of Leeds, UK;1. St George Hospital Cancer Care Centre, Kogarah, Australia;2. Centre for Medical Radiation Physics, University of Wollongong, Australia;3. Medical Physics Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy;1. Department of Medical Physics, Royal Adelaide Hospital, Adelaide, South Australia, Australia;2. Institute for Photonics & Advanced Sensing and School of Chemistry & Physics, University of Adelaide, Adelaide, South Australia, Australia;3. Department of Medical Physics, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran;1. Leeds Cancer Centre, UK;2. Sir Anthony Mamo Oncology Centre, San Gwann, Malta;3. University of Leeds, UK;1. Alfred Health Radiation Oncology, Alfred Health, Melbourne, VIC, Australia;2. School of Science, RMIT University, Melbourne, VIC, Australia;3. Central Clinical School, Monash University, Melbourne, VIC, Australia;4. School of Physics, University of Sydney, Camperdown, NSW, Australia |
| |
| Abstract: | PurposeDose to the rectum during brachytherapy treatment may differ from an approved treatment plan which can be quantified with in vivo dosimetry (IVD). This study compares the planned with in vivo doses measured with MOSkin and PTW 9112 rectal probe in patients undergoing CT based HDR cervical brachytherapy with Co-60 source.MethodsDose measurement of a standard pear-shaped plan carried out in phantom to verify the MOSkin dose measurement accuracy. With MOSkin attached to the third diode, RP3 of the PTW 9112, both detectors were inserted into patients’ rectum. The RP3 and MOSkin measured doses in 18 sessions as well as the maximum measured doses from PTW 9112, RPmax in 48 sessions were compared to the planned doses.ResultsPercentage dose differences ΔD (%) in phantom study for two MOSkin found to be 2.22 ± 0.07% and 2.5 ± 0.07%. IVD of 18 sessions resulted in ΔD(%) of ?16.3% to 14.9% with MOSkin and ΔD(%) of ?35.7% to ?2.1% with RP3. In 48 sessions, RPmax recorded ΔD(%) of ?37.1% to 11.0%. MOSkin_measured doses were higher in 44.4% (8/18) sessions, while RP3_measured were lower than planned doses in all sessions. RPmax_measured were lower in 87.5% of applications (42/47).ConclusionsThe delivered doses proven to deviate from planned doses due to unavoidable shift between imaging and treatment as measured with MOSkin and PTW 9112 detectors. The integration of MOSkin on commercial PTW 9112 surface found to be feasible for rectal dose IVD during cervical HDR ICBT. |
| |
| Keywords: | Rectal dose Intracavitary brachytherapy PTW 9112 semiconductor |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
